Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 04 Mar, 2022
  • 2 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

biology (secondary AML, therapy related AML). Patients with a low risk of relapse will be allocated to consolidation, with three courses of high doses of Ara-C (HiDAC), or two courses of HiDAC with

secondary acute myeloid leukemia
cell transplantation
cytarabine/daunorubicin
induction chemotherapy
myelodysplastic syndromes
  • 32 views
  • 07 Oct, 2021
  • 10 locations
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

secondary acute myeloid leukemia
azacitidine
myeloid leukemia
hydroxyurea
decitabine
  • 0 views
  • 25 Mar, 2022
  • 1 location
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

cladribine
filgrastim
secondary acute myeloid leukemia
hemolysis
direct bilirubin
  • 60 views
  • 01 May, 2022
  • 1 location
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old

chronic myelomonocytic leukemia
secondary acute myeloid leukemia
myeloid leukemia
cancer
leukemia
  • 0 views
  • 10 May, 2022
  • 3 locations
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

unrelated donors in patients with MDS or secondary AML. The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem

cell transplantation
fludarabine
cyclophosphamide
busulfan
  • 28 views
  • 07 Nov, 2020
  • 1 location
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, or

refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
secondary acute myeloid leukemia
  • 0 views
  • 30 Jul, 2021
  • 9 locations
Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

This phase II trial of the impact of clinicogenetic risk-stratified management on outcomes of acute myeloid leukemia in older patients is to determine the rate of complete remission and mortality at 90 days in the entire cohort of older patients (60 years) with newly diagnosed acute myeloid leukemia, who receive …

idarubicin
daunorubicin
treatment related aml
remission
decitabine
  • 8 views
  • 06 Aug, 2021
  • 2 locations
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

This phase IB/II trial studies the best dose of TP-0903 and how well it works when given alone or with azacitidine in treating patients with FLT3 gene mutated acute myeloid leukemia. TP-0903 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy …

cancer
azacitidine
ejection fraction
  • 0 views
  • 23 Mar, 2022
  • 1 location